ACTRIMS 2023: Loss of myelin in spinal cord tied to MS disability
More loss in cervical region also linked to worse motor function by Lindsey Shapiro, PhD | February 27, 2023 A…
MS and Concussions
MS and Concussions The exact cause of MS isn’t known, although experts believe that a number of things play…
Stuart Schlossman
‘Usual Suspect’ Lesions Appear Not to Cause Most Severe Disability in Multiple Sclerosis Patients
Presented at 2023 ACTRIMS in San Diego, Ca Summary: While brain lesions may be a key marker for Multiple Sclerosis, they…
Stuart Schlossman
Study helps make clear distinctions between MS, MOGAD (Myelin oligodendrocyte glycoprotein antibody-associated disease)
February 25, 2023 The study was presented at the 2023 #ACTRIMS forum A new study set out to assess potentially…
Stuart Schlossman
Favorable Safety Outcomes Observed in Ozanimod (#Zeposia) Over Diroximel Fumarate (Vumerity)
Feb 26, 2023 – Marco Meglio – #ACTRIMS Conferences: Americas Committee for Treatment and Research in Multiple Sclerosis…
Stuart Schlossman
Metabolic Changes, Cognitive Improvements in Multiple Sclerosis Observed Through Intermittent Calorie Restriction
Feb 27, 2023 – Marco Meglio Compared with those on an unrestricted diet, patients with MS on intermittent calorie restriction…
Stuart Schlossman
Gauging MS Disease Activity Through Octave’s MSDA Test
Feb 24, 2023 Taylor Gonyou, DO The multiple sclerosis fellow at Michigan Institute for Neurologic Disorders provided perspective on…
Stuart Schlossman
BTK Inhibitor Evobrutinib Displays Superior Efficacy Compared With Anti-CD20 Treatment for MS
Feb 25, 2023 – Isabella Ciccone, MPH A preclinical assessment of evobrutinib showed it demonstrated superior efficacy in targeting compartmentalized…
Stuart Schlossman
Ocrelizumab and Rituximab Demonstrate Similar Safety, Efficacy in Treatment of Multiple Sclerosis
Treatment with either rituximab and ocrelizumab, 2 FDA-approved therapies that target CD20, resulted in similar odds of experiencing a clinical…
Stuart Schlossman
Omega-3 fatty acid reduced disease severity in MS mouse model
Study findings could lead to new solutions in managing MS symptoms by Marisa Wexler, MS | February 16, 2023 Treatment…
Stuart Schlossman
